DCOY · Decoy Therapeutics Inc. · Shareholders & Ownership
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Every disclosed holder of DCOY in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns DCOY
13F quarter Jun 30, 2026| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 4,317 | 0.66% |
| Insiders (Forms 3, 4, 5) | 0 | 0.00% |
| 13D/G-only blocks | 140,158 | 21.39% |
| Remaining | 510,710 | 77.95% |
| Registered funds (N-PORT, not summed) | 9,688 | 1.48% |
Shares outstanding: 655,185, the issuer's latest cover-page count restated onto today's split basis.
Insiders are listed but not summed: the issuer has more than one class of common stock and Forms 3, 4 and 5 report one issuer-wide balance across them.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of DCOY
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
ARMISTICE CAPITAL, LLC
13G
CIK 1601086 · Registered investment adviser · Jun 30, 2026
Rule 13d-1(b), qualified institution
|
65,503 | ||
| 2 |
|
59,047 | ||
| 3 |
PIERCE FREDERICK II
Insider
CIK 1229055 · Aug 31, 2026
Chief Executive Office, issuer-wide, not summed
|
34,844 | ||
| 4 |
|
15,608 | ||
| 5 |
|
11,363 | ||
| 6 |
Fidelity Extended Market Index Fund
Fund
S000006021 · Registered fund · May 31, 2026
Fidelity Concord Street Trust, not summed
|
5,156 | ||
| 7 |
Hibner Barbara Louise
Insider
CIK 2079512 · Aug 31, 2026
Chief Scientific Officer, issuer-wide, not summed
|
4,216 | ||
| 8 |
VANGUARD CAPITAL MANAGEMENT LLC
13F
CIK 2100119 · Registered investment adviser · Jun 30, 2026
|
4,034 | ||
| 9 |
VANGUARD EXTENDED MARKET INDEX FUND
Fund
S000002841 · Registered fund · Jun 30, 2026
VANGUARD INDEX FUNDS, not summed
|
4,034 | ||
| 10 |
Marschel Peter Klaus
Insider
CIK 2079859 · Aug 31, 2026
Chief Business Officer, issuer-wide, not summed
|
3,900 | ||
| 11 |
|
3,418 | ||
| 12 |
|
3,002 | ||
| 13 |
|
2,002 | ||
| 14 |
Lieber Jonathan I
Insider
CIK 1350090 · Aug 31, 2026
Chief Financial Officer, issuer-wide, not summed
|
2,002 | ||
| 15 |
|
2,001 | ||
| 16 |
|
2,000 | ||
| 17 |
Fidelity Series Total Market Index Fund
Fund
S000065248 · Registered fund · May 31, 2026
Fidelity Concord Street Trust, not summed
|
477 | ||
| 18 |
Tower Research Capital LLC (TRC)
13F
CIK 1533421 · Unknown · Jun 30, 2026
|
256 | ||
| 19 |
UBS Group AG
13F
CIK 1610520 · Bank · Jun 30, 2026
|
25 | ||
| 20 |
Horizon Kinetics Medical ETF
Fund
S000078972 · Registered fund · Jun 30, 2026
Listed Funds Trust, not summed
|
21 | ||
| 21 |
Caitong International Asset Management Co., Ltd
13F
CIK 1963355 · Unknown · Jun 30, 2026
|
2 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.